Physician profile
Sheri Boyd
NPI 1669443115
$8,735.17
in general payments reported to CMS, 2019-2025
36 companies · $1,041 in 2025
The $1,041 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,371 · 2020: $284 · 2021: $455 · 2022: $505 · 2023: $929 · 2024: $1,150 · 2025: $1,041.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,120.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $3,385.87 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $1,109.41 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $733.24 | 2019-2024 | Xarelto |
| Amgen INC. | $496.53 | 2019-2025 | Repatha, Repatha |
| Abbott Laboratories | $347.10 | 2019-2024 | Gallant, Aveir |
| Amarin Pharma, INC. | $329.87 | 2019-2022 | |
| Boston Scientific Corporation | $258.82 | 2019-2025 | Wolverine Coronary Cutting Balloon, Watchman Flx, Rotapro |
| Regeneron Healthcare Solutions, INC. | $241.14 | 2019-2024 | Evkeeza, Praluent |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $166.22 | 2020-2025 | Lifevest |
| Pfizer INC. | $156.27 | 2020-2025 | |
| Akcea Therapeutics, INC. | $153.50 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $130.54 | 2019-2025 | Farxiga, Lokelma, Brilinta |
| Merck Sharp & Dohme LLC | $119.50 | 2021-2025 | Verquvo |
| Lexicon Pharmaceuticals, INC. | $117.51 | 2023-2024 | Inpefa |
| Novo Nordisk INC | $114.97 | 2024-2025 | Ozempic |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biosense Webster, INC. | $106.33 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $104.15 | 2024-2025 | Uptravi, Opsumit, Opsynvi |
| Medtronic, INC. | $79.00 | 2025 | Azure Xt Dr Mri Surescan |
| Atricure, INC. | $72.57 | 2025 | Epi-Sense Guided Coagulation System With Visitrax, Synergy Ablation System, Atriclip Laa Exclusion System |
| E.R. Squibb & Sons, L.L.C. | $68.92 | 2024-2025 | Camzyos, Eliquis |
| Scpharmaceuticals INC. | $59.09 | 2023-2024 | |
| Cvrx, INC. | $50.68 | 2022-2023 | Barostim Neo System |
| Lemaitre Vascular, INC. | $43.89 | 2019 | |
| Esperion Therapeutics, INC. | $30.43 | 2021 | |
| Baxter Healthcare | $28.86 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Kowa Pharmaceuticals America, INC. | $28.07 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $27.53 | 2024 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $26.05 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.98 | 2025 | |
| Chiesi USA, INC. | $21.84 | 2024 | Juxtapid |
| Glaxosmithkline, LLC. | $21.82 | 2025 | Arexvy, Shingrix |
| Lundbeck LLC | $19.78 | 2019 | |
| Inspire Medical Systems, INC. | $19.30 | 2025 | Inspire |
| Arbor Pharmaceuticals, INC. | $13.69 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.53 | 2025 | Jardiance |
| Inari Medical, INC. | $13.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheri Boyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.